First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
High interest rates negatively impact Tonix through two channels: (1) Valuation compression - biotech DCF models discount future cash flows…
Watch on earnings: Monthly cash burn rate and total cash/equivalents balance - determines financing urgency and runway, Phase 2/3 trial enrollment completion percentages and data readout timelines for TNX-102 SL and TNX-1300, Nasdaq Biotechnology Index (NBI) performance as proxy for biotech funding environment and risk appetite.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $34M to $79M as phase 2/3 clinical trial readouts for tnx-102 sl (fibromyalgia), tnx-1300 (cocaine intoxication).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.